Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
M.I. Volkova
Observed names:
M. Volkova,
M. I. Volkova
Institutions:
Russian Medical Academy of Continuous Professional Education,
Ministry of Health of the Russian Federation,
City Clinical Hospital
Observed institutions:
Russian Medical Academy of Continuous Professional Education,
Ministry of Health of the Russian Federation,
City Clinical Hospital
ORCID:
0000-0001-7754-6624
Observed ORCID:
0000-0001-7754-6624
OpenAlex ID:
A5041014981
Analysis of the Efficacy and Safety of Avelumab Maintenance Therapy in Subgroups of Patients with Metastatic Urothelial Carcinoma in Real-World Practice (RAVE-Bladder Study)
2026
·
Ya. V. Gridneva
, M. I. Volkova
, et al.
·
Malignant tumours
·
1
PDF
561P Immune-related adverse events associated with first-line immune checkpoint inhibitors-based therapy for metastatic renal cell carcinoma
2025
·
M.I. Volkova
, T.A. Nersesova
, et al.
·
Annals of Oncology
215eP Endocrine adverse events as an efficacy biomarker in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitors-based therapy
2025
·
M. Volkova
, M.A. Lyadova
, et al.
·
Immuno-Oncology Technology
16P High fibrinogen levels affect the clinical outcomes of nivolumab in the second-line treatment of metastatic renal cell carcinoma patients: A prospective cohort study
2022
·
I. Tsimafeyeu
, M.I. Volkova
, et al.
·
Immuno-Oncology Technology
PDF
Show more works
View as search
Works count:
4
Citation count:
1
H-index:
1
I10-index:
Year
Topic
Type